Skip to main content
There is not a single one of us in rheumatology who hasn’t prescribed steroids, but we really need to reconsider how much and how often we use them.
Therapeutic Options for VEXAS
Combined 4 tofacitinib RCTs (4404 pts) found baseline probable major depression or anxiety disorder in 44.5%, 39.8%, 45.

Dr. John Cush RheumNow

2 years 9 months ago
Combined 4 tofacitinib RCTs (4404 pts) found baseline probable major depression or anxiety disorder in 44.5%, 39.8%, 45.4%, 39.1% on TOFA 5 BID, TOFA 10 BID, adalimumab, & placebo. Effective RA Rx w/ Tofa or ADA lead to improved depression and anxiety https://t.co/y6UoFXANo7 https://t.co/aV5uV9qWbz
#PsA Metanalysis of 54 RCTs (22621 pts; 49% male). Males had less severe Dz than females (TJC, HAQ, global, pain) but hi

Dr. John Cush RheumNow

2 years 9 months ago
#PsA Metanalysis of 54 RCTs (22621 pts; 49% male). Males had less severe Dz than females (TJC, HAQ, global, pain) but higher PASI & CRP. Males had higher ACR20 resp to inhib of IL-17 (OR 1.7), IL-23 (1·46), 12/23 (2·67), TNF (1·55) but no diff w/ JAK/Tyk2 https://t.co/fOl9zpCv1G https://t.co/JXAj5sG1bf
Substudy of the ADVOCATE trial looked at 214 ANCA assoc vasculitis pts treated with #RTX; avacopan Rx showed improved re

Dr. John Cush RheumNow

2 years 9 months ago
Substudy of the ADVOCATE trial looked at 214 ANCA assoc vasculitis pts treated with #RTX; avacopan Rx showed improved recovery of renal function, faster reduction in albuminuria and lower glucocorticoid toxicity compared to a prednisone taper. https://t.co/ujynO9oAj0 https://t.co/JWBrKzGux1
MSK disorders affects >1.63 billion worldwide. Global Burden of Diseases study estimates that by 2050, 1.06 billion

Dr. John Cush RheumNow

2 years 9 months ago
MSK disorders affects >1.63 billion worldwide. Global Burden of Diseases study estimates that by 2050, 1.06 billion will have "other" MSK Dz (excluding RA, OA, LBP, gout, neck pain) - up from 494 million in 2020. https://t.co/cCf8biqjx1 https://t.co/Xv9qlvQl90
International study of 600 lupus pts - photosensitivity seen in 65% & was associated other lupus skin Dz (OR = 3.8).

Dr. John Cush RheumNow

2 years 9 months ago
International study of 600 lupus pts - photosensitivity seen in 65% & was associated other lupus skin Dz (OR = 3.8). Fatigue was the most frequently reported systemic manifestation (82%). https://t.co/kjuvRZnB13 https://t.co/UTMNgiXbZZ
TNF inhibitors revolutionised the treatment of rheumatoid arthritis. While highly effective for the joint manifestations of the disease, a note of caution was sounded regarding the potential for worsening of ILD with these agents. Within this framework, a study by England et al presented at ACR23 was highly relevant.
IgG4-related disease describes a group of fibroinflammatory diseases whose features may include autoimmune pancreatitis, swelling of or within an organ system, salivary gland disease, swollen lymph nodes, skin manifestations, and symptoms consistent with allergies or asthma. While remission induction treatment with glucocorticoids has proven effective, the high relapse tendency is an ongoing challenge for clinicians.
Psoriatic Arthritis Topic Panel
Can We Prevent RA? Results from the APIPPRA Trial

Dr. Jonathan Kay talks with Dr. Andrew Cope about abstract 0835 at t

Dr. John Cush RheumNow

2 years 9 months ago
Can We Prevent RA? Results from the APIPPRA Trial Dr. Jonathan Kay talks with Dr. Andrew Cope about abstract 0835 at the 2023 ACR Convergence meeting in San Diego, CA https://t.co/d4nXIQbvEC https://t.co/n9kvz8Z8tY
Long term F/U of early RA, T2T RCTs (n 1616) finds excess mortality > 10yrs for BeST (SMR 1.32) & IMPROVED (SMR

Dr. John Cush RheumNow

2 years 9 months ago
Long term F/U of early RA, T2T RCTs (n 1616) finds excess mortality > 10yrs for BeST (SMR 1.32) & IMPROVED (SMR 1.33) RCTs; highest in ACPA+ smokers (SMR 2.80 & 2.14); Cancer main cause. SMR incr 34% & 13% for ea 1 pt incr in DAS https://t.co/mXrCnzfe4W https://t.co/wWxfI1kMbm
Simulated Trials to Counter ORAL Survelliance

Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in

Dr. John Cush RheumNow

2 years 9 months ago
Simulated Trials to Counter ORAL Survelliance Dr. Jack Cush and Dr. Janet Pope at the 2023 ACR Convergence meeting in San Diego, CA. https://t.co/XF8zlISqKC https://t.co/yXn7KADIdo
Undiagnosed IBD in AxSpA

Dr. Eric Dein (Summit, New Jersey) discusses Abstract #0495 presented at the ACR 2023 Converg

Dr. John Cush RheumNow

2 years 9 months ago
Undiagnosed IBD in AxSpA Dr. Eric Dein (Summit, New Jersey) discusses Abstract #0495 presented at the ACR 2023 Convergence meeting in San Diego. https://t.co/l0pAs5u9nY https://t.co/BY5HwRlWXo
×